Kovovax COVID vaccine made by Serum triggers immune response to Omicron

Serum Institute is the world’s largest producer of vaccines and calls the Novavax shot kovovax,

Novavax and its partner Serum Institute of India have agreed to send over 1.1 billion doses of Novavax’s vaccine, NVX-CoV2373, to Kovax.

“In the midst of an emerging epidemic, NVX-CoV2373 showed robust immune responses against omicron and other circulating variants. We are encouraged that the increased responses against all variants stem from the high vaccine efficacy in our phase 3 clinical trials. were comparable with those associated, suggesting that NVX-CoV2373 may play a key role in the ongoing fight against new variants,” said Gregory M., Novavax’s President of Research and Development. Glenn said.

Novavax is working on developing an Omicron-specific vaccine and said on Wednesday it hopes to begin manufacturing a dose of the variant-specific shot in January.

“Given the continuing evolution of the coronavirus, development of an Omicron vaccine may be necessary. Novavax has cloned, expressed and characterized the Omicron spike protein vaccine and will soon enter the GMP-phase of production. We expect to begin clinical studies in the first quarter of 2022,” Glenn said.

Novavax’s two-dose, protein-based vaccine Kovovax was recently authorized for use by EU regulators and the World Health Organization. It was previously ratified by countries including Indonesia and the Philippines, but not the United States.

“CovoVaxM was evaluated under the WHO EUL process based on a review of data on quality, safety and efficacy, a risk management plan, programmatic suitability, and construction site inspections conducted by the Drugs Controller General of India. The Technical Advisory Group for Emergency Use Listing (TAG-EUL), convened by WHO and composed of experts from around the world, has determined that the vaccine meets WHO standards for protection against COVID-19, which That’s more than the benefits of the vaccine. any risk, and the vaccine can be used globally,” the WHO had said while issuing an emergency use list.

Commenting on WHO’s approval, Serum Institute CEO Adar Poonawalla said in a recent tweet, “This is yet another milestone in our fight against COVID-19, Covovax is now available to WHO for emergency use. has been approved, showing excellent safety and efficacy. Thank you all for a great collaboration.”

Serum Covishield also manufactures the COVID vaccine which is authorized for use in India.